Provectus announced the addition of Aru Narendran, MD, PhD to the Company's Scientific Advisory Board. Dr. Narendran is a professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology at the University of Calgary'sCumming School of Medicine (Calgary, Alberta, Canada), and holds the Kids Cancer Care Foundation Endowed Chair in Clinical and Translational Research in pediatric oncology.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.199 USD | +0.25% | +2.16% | +107.29% |
1st Jan change | Capi. | |
---|---|---|
+107.29% | 83.28M | |
-2.63% | 103B | |
+1.67% | 95.28B | |
+1.75% | 22.15B | |
-15.31% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.27% | 16.05B | |
+4.02% | 13.68B | |
+34.74% | 12.17B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board